| This week's sponsor is Premier Research. | |  | Overcoming Risk in Oncology Drug Development
Oncology drug development is fraught with obstacles and risks, and you must carefully plan each step. Click here for tips on finding the fast track. Premier Research. It's what we do. Best. |
Today's Rundown Featured Story | | | Tuesday, May 7, 2019 Verve Therapeutics is launching with $58.5 million, access to gene-editing tech from the likes of the Broad Institute and Beam Therapeutics, and longtime cardiologist and geneticist Sekar Kathiresan at its helm. |
|
|
Top Stories Tuesday, May 7, 2019 Bahija Jallal, David Berman, Koustubh Ranadel, and now Mohammed Dar lines up as the latest AstraZeneca/MedImmune executive to jump ship into U.K. biotech Immunocore. Tuesday, May 7, 2019 Though a rare condition, the debilitating wasting disease spinal muscular atrophy is gaining a large biopharma interest (and price tags in the millions of dollars), and Roche, with partner PTC Therapeutics, are the latest companies to show their hand in improving kids’ ability to move with the genetic disorder. Tuesday, May 7, 2019 Viela tested inebilizumab in patients with neuromyelitis optica spectrum disorders, a rare disease in which the immune system attacks the optic nerves, spinal cord and brain. The drug reduced these attacks by 73%. Tuesday, May 7, 2019 Confo Therapeutics has raised €30 million ($34 million) to take compounds targeting difficult-to-drug GPCRs into clinical development. The series A sets Confo up to advance drugs derived from a novel way of stabilizing GPCRs and performing more sensitive screens. Monday, May 6, 2019 Promethera Biosciences has raised €39.7 million ($44.4 million) to put its liver disease cell therapy through clinical trials. The series D round comes as Promethera prepares to start testing its lead drug in end-stage NASH patients. Tuesday, May 7, 2019 Artificial intelligence in drug development is among the hottest buzzwords in biopharma right now, but often real progress from it is hampered by a lack of expertise and less than equal access to its latent potential. Resources Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. Sponsored by: AlphaSense What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve? Sponsored by: JPEO-CBRND – Medical Countermeasure Systems MCS is currently seeking broad-based industry/academia collaboration on research and prototype work in technical areas related to developing medical countermeasures for the Joint Warfighter. Sponsored by: Outer Edge Technology Learn how the cloud can support the performance and security requirements for validated, mission-critical applications historically designed and implemented exclusively via on-premises deployment. Sponsored by: Elemental Machines Learn how cloud-connected IoT sensors are transforming operations in leading life science labs. Read our white paper “The Smart Lab”. Presented by: Total Brain Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy. Sponsored by: Veradigm Prescription price transparency technology is here – but is it making a difference? Find out HERE. Sponsored by: Strativity Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver? Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
